A Japan-based corporate VC fund primarily makes early stage investments solely in the Life Sciences. The firm raised a new fund in 2014 and looks to make about 2-3 new investments in the next 12 months. The firm typically allocates USD 1-2 million per round and up to USD 3 million per company. The firm can invest globally, but at present has a primary focus on opportunities in the USA. The firm acts as a co-investor.
The fund focuses on therapeutic drug discovery platforms. For therapeutics, the firm looks for small molecules, biologics, as well as biosimilars and reformulated drugs. The firm is opportunistic in terms of indications and is particularly interested in orphan indications and in products that are targeting Japan as a future market. The firm will consider products in all stages of development, but typically invests in products that are in pre-clinical and early-clinical stages.
The firm will only co-invest with other institutional investors in opportunities outside of Japan; companies backed solely by angel investors are not of interest. The firm prefers opportunities with a syndicate and/or lead investor in place. The firm typically requests board observation rights in its portfolio companies.
If you are interested in more information about this investor and other investors tracked by LSN, please email email@example.com